Chuntuan Li

Aug 29, 2024 | onlinelibrary.wiley.com | Chuntuan Li |shengquan Liu |Jingjing Gao |Yanjun He

1 INTRODUCTION The clinical management of Mantle cell lymphoma (MCL) continues to face enduring challenges due to its incurable nature, frequent recurrence, resistance to drugs, and limited survival rates.1 Despite advancements such as novel therapies targeting CD20 and Bruton's tyrosine kinase (BTK) inhibitors, which initially showed significant clinical remission, patients eventually relapse due to chemotherapy resistance, leading to fatal outcomes.2-5 The Hh pathway has been recognized as...